Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal Sees No Rx Distribution Disruptions After April 1 Fee-For-Service Deadline

This article was originally published in The Pink Sheet Daily

Executive Summary

Most drug manufacturers have agreed in principle to fee-for-service distribution contracts, Cardinal CEO Walter says. Negotiations are now focused on price, not the methodology for paying wholesalers, he says.

You may also be interested in...



McKesson In Final Phase Of Negotiating Fee-For-Service Contracts

The wholesaler anticipates 80% of compensation from manufacturers will be recorded under the new contract model by Oct. 1. Pfizer continues to be a significant holdout within the transition to fee-for-service, McKesson says.

McKesson In Final Phase Of Negotiating Fee-For-Service Contracts

The wholesaler anticipates 80% of compensation from manufacturers will be recorded under the new contract model by Oct. 1. Pfizer continues to be a significant holdout within the transition to fee-for-service, McKesson says.

ABC Still Optimistic On Fee-For-Service Despite Dropping Earnings Estimates

AmerisourceBergen still aims to have most manufacturers under fee-for-service agreements by the end of 2005. Although ABC has not set a March 31 deadline for fee-for-service contracts like Cardinal and McKesson, CEO Yost says "there is nothing in the market place that would imply that we are slower" at making the transition.

Related Content

Topics

UsernamePublicRestriction

Register

PS061938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel